Core Viewpoint - Bristol Myers Squibb (BMS) has signed an agreement to sell 60% of its stake in Shanghai Bristol-Myers Squibb Pharmaceutical Co., Ltd. (SASS factory), while reaffirming its commitment to the Chinese market and continuing investments under its "China 2030 Strategy" [1][6]. Company Overview - Shanghai Bristol-Myers Squibb Pharmaceutical Co., Ltd. is currently owned 60% by BMS (China) Investment Co., Ltd., 30% by Shanghai Pharmaceuticals, and 10% by China National Pharmaceutical Group Asset Management Co., Ltd. [1] - The company produces several well-known pharmaceutical products, including antibiotics and antihypertensive medications [4][5]. Product Portfolio - The company manufactures various drugs, including: - Entecavir tablets (for hepatitis B treatment) - Cephalexin capsules (antibiotic) - Acetaminophen solutions (common cold and fever medication) - Fosinopril sodium tablets and Metformin hydrochloride tablets (antihypertensive medications) [2][3][6]. Market Strategy - BMS aims to accelerate the introduction of innovative therapies across various disease areas and enhance drug accessibility for Chinese patients [1][6]. - The company has shifted its focus towards a diversified biopharmaceutical strategy, concentrating on major disease areas such as oncology, hematology, and immunology [6]. Recent Developments - The potential buyer of the stake is rumored to be Hillhouse Capital, although BMS has not confirmed this information [3]. - Recent trends show a significant number of equity changes among foreign pharmaceutical companies in China, indicating a dynamic market environment [4][6]. Leadership Changes - Qian Jiang has taken over as the General Manager of BMS China, bringing experience from previous roles at Pfizer, Novartis, and Eli Lilly [7].